300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
Oil and Gas
InsurTech
Social Impact
Retail
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
B2B
Blockchain
Social Network
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Theatre
Medical
Venture Capital
Recruiting
Web3
Cannabis
LGBT
Celebrity
Fashion
Climate
Mobile Apps
Life Science
Wine and Spirits
Social
Food and Beverage
Publishing
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Beauty
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Infrastructure
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Greece
Oman
Poland
Puerto Rico
Cameroon
Guernsey
Andorra
Colombia
Sudan
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Botswana
Paraguay
Japan
Ireland
Canada
United Kingdom
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Peru
Mongolia
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Sarper Tanli, Angel Investor

Sarper Tanli

Angel Investor

Dubai, United Arab Emirates

Sarper Tanli is a seed investor in Dubai focused on Women's and mHealth. Sarper brings over 28 years of experience in medical and healthcare management, planning, and development, and operations. He holds a Medical Doctor and a Masters in Healthcare Administration degree from Istanbul University as well as a Ph.D. degree in Healthcare Management from Marmara University. He worked in International divisions of HoustonMethodist Hospital Global and Harvard Medical International in the region during the last 15 years. Dr. Sarper started the first home health and disease management company in Turkey in early 2002. He has held key positions in the development of Dubai Healthcare City.

Total investments:
1
Last investment:
Lead investor:
0%

Last updated:

Industries Sarper Tanli invests in

Women'smHealthHealth CarePersonal Health

Stages Sarper Tanli invests in

Seed

Countries Sarper Tanli invests in

United Arab Emirates

Investment Focus

Industry

  • Women's 1 (100%)
  • mHealth 1 (100%)
  • Health Care 1 (100%)
  • Personal Health 1 (100%)

Investments

CompanyDescriptionRoundLinks
Nabta Health Nabta Health
Nabta’s unique model of hybrid healthcare seamlessly combines digital health with traditional healthcare to improve health outcomes in women living with NCDs.The growing epidemic of NCDs threatens the ambition of countries around the world to achieve sustainable, universal access to health and universal health coverage for their populations.Moreover, NCDs leave populations more susceptible to communicable diseases such as coronaviruses, influenza and tuberculosis. During the COVID-19 pandemic of 2020, 78% of people admitted to ICU in the US and 94% of those who died had underlying health conditions (CDC).NCDs remain underesearched and underserved in women. Until the mid-1990s, clinical research and clinical trials largely excluded women. Only since 1994, when the United States’ National Institutes of Health (NIH) mandated that women and minorities were to be included as subjects in clinical research, has the research community entertained the fact that sex and/or gender differences might affect clinical outcomes.Today, women using drugs that were approved by the early 90s, are 50–75% more likely than men to suffer adverse reactions to those therapies. Ironically, a significant proportion of the drugs in this category are those designed to treat or manage NCDs. Examples include statins and potassium channel-blockers used to manage cardiovascular disease or hypoglycaemic drugs such as Rezulin used to control diabetes.Nabta’s first hybrid care pathway supports women in preventing, identifying and managing Polycystic Ovary Syndrome (PCOS). PCOS is a hormonal disorder responsible for 70% of female fertility issues. Women who use Nabta’s platform will be able to achieve a formal diagnosis of PCOS within 90 days. The average time taken to diagnose PCOS currently is 2.5 years. $1.5M / Seed / Feb 22, 2022

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
Oil and Gas
InsurTech
Social Impact
Retail
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
B2B
Blockchain
Social Network
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Theatre
Medical
Venture Capital
Recruiting
Web3
Cannabis
LGBT
Celebrity
Fashion
Climate
Mobile Apps
Life Science
Wine and Spirits
Social
Food and Beverage
Publishing
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Beauty
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Infrastructure
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Greece
Oman
Poland
Puerto Rico
Cameroon
Guernsey
Andorra
Colombia
Sudan
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Botswana
Paraguay
Japan
Ireland
Canada
United Kingdom
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Peru
Mongolia
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Sarper Tanli invest in?

Sarper Tanli invests primarily in Women's, mHealth and Health Care startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in United Arab Emirates. The Investment Focus section breaks down every industry, stage and country in the portfolio.

When did Sarper Tanli last invest?

The most recent investment recorded for Sarper Tanli closed in Feb 2022. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Sarper Tanli Sarper Tanli Find email